KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Total Current Liabilities (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Total Current Liabilities data on record, last reported at $881.6 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 21.96% year-over-year to $881.6 million; the TTM value through Dec 2025 reached $881.6 million, down 21.96%, while the annual FY2025 figure was $881.6 million, 21.96% down from the prior year.
  • Total Current Liabilities reached $881.6 million in Q4 2025 per AMRX's latest filing, up from $862.1 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $1.1 billion in Q4 2024 and bottomed at $602.0 million in Q1 2022.
  • Average Total Current Liabilities over 5 years is $850.4 million, with a median of $826.2 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: crashed 34.02% in 2021, then skyrocketed 47.59% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $677.2 million in 2021, then increased by 11.16% to $752.8 million in 2022, then rose by 12.46% to $846.6 million in 2023, then skyrocketed by 33.45% to $1.1 billion in 2024, then decreased by 21.96% to $881.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $881.6 million in Q4 2025, $862.1 million in Q3 2025, and $1.1 billion in Q2 2025.